Many people have heard of psoriasis, but few truly understand this disease. It is not just a "skin disease," but a chronic immune-mediated inflammatory disease driven by complex immune disorders.
The typical manifestations of psoriasis include well-demarcated erythema, covered with silvery white scales, often accompanied by itching and dryness. In severe cases, skin lesions can spread all over the body. According to epidemiological data, more than 100 million patients worldwide are affected by psoriasis, and the patient population in China is also considerable. More importantly, it is not just a superficial skin problem — some patients may experience complications such as psoriatic arthritis and metabolic abnormalities, making it a true systemic disease that long-term impairs patients' quality of life and mental health.
For a long time in the past, the treatment options for psoriasis were relatively limited, mainly relying on three types of methods:
✅ Topical drugs: Such as glucocorticoids and vitamin D3 derivatives, suitable for mild skin lesions, only relieving symptoms locally;
✅ Phototherapy: Using specific wavelengths of light to irradiate the lesion area to assist in controlling inflammation, but it requires long-term trips to the hospital and has limited effects on severe patients;
✅ Traditional immunosuppressants: Exerting effects by broadly suppressing the immune system, which can control the condition but have relatively obvious side effects and require close monitoring during long-term use.
These methods are effective for some mild patients, but for moderate to severe psoriasis patients, problems such as poor treatment effect, high recurrence rate, and insufficient long-term safety have always been insurmountable limitations.
Targeted Immunotherapy Completely Changes the Pattern of Psoriasis Treatment
With the in-depth development of immunological research, scientists have finally uncovered the core pathogenic code of psoriasis — the IL-17 inflammatory pathway, which is the key driving factor leading to the disease.
Simply put, IL-17A is an important pro-inflammatory cytokine that overactivates skin inflammatory responses, accelerates the abnormal proliferation of keratinocytes, thereby forming the typical erythema and scales of psoriasis, and even inducing complications such as joint inflammation. Finding this "target" is equivalent to finding a "breakthrough" for treatment.
In recent years, a class of targeted biological agents — IL-17A inhibitors, has emerged, completely rewriting the treatment rules of psoriasis. For example, drugs such as Secukinumab and Ixekizumab have been widely used worldwide.
By precisely blocking IL-17A inflammatory signals, they can not only quickly resolve skin lesions but also achieve long-term stable disease control, allowing many moderate to severe patients to regain a normal life.
In the process of continuous exchanges with the global pharmaceutical industry, DengYue Medicine has also noticed that with the in-depth development of immunological research, more and more innovative drugs targeting the IL-17 pathway are entering the clinical application stage, including some R&D achievements from Chinese biopharmaceutical enterprises.
The Rise of Chinese Innovative Drugs Brings Local New Options for Patients
With the continuous improvement of China's biopharmaceutical R&D capabilities, in the field of targeted psoriasis treatment, we also have our own "Chinese innovative drugs." More and more locally developed IL-17A targeted biological agents have entered clinical practice, benefiting patients and breaking the monopoly of imported drugs.
Today, we will introduce two IL-17A monoclonal antibodies independently developed in China, specifically designed for moderate to severe psoriasis patients:
1. Vunakizumab Injection
Independently developed by Jiangsu Hengrui Pharmaceuticals, it is a Class 1 innovative biological drug in China. Its core mechanism of action is to specifically bind to IL-17A, precisely block the inflammatory signaling pathway, fundamentally reduce skin inflammatory responses, and inhibit the progression of skin lesions.
At present, it has been approved for two indications in China, covering both skin and joint symptoms:
✅ Moderate to severe plaque psoriasis (adult patients suitable for systemic treatment or phototherapy);
✅ Active ankylosing spondylitis (radiographically positive axial spondyloarthritis) in adult patients.
2. Xeligekimab Injection
Developed by Zhixiang Jintai Biopharmaceutical, it is also a domestic innovative biological agent targeting the IL-17A. By precisely inhibiting IL-17A-mediated inflammatory responses, it effectively improves psoriasis skin lesions and reduces recurrence.
Its approved indications are the same as Vunakizumab, providing multiple options for patients:
✅ Moderate to severe plaque psoriasis (adult patients suitable for systemic treatment or phototherapy);
✅ Ankylosing spondylitis (radiographically positive axial spondyloarthritis) in adult patients.
From "Broad-Spectrum Suppression" to "Precision Targeting": The Significance of Medical Progress
The development of psoriasis treatment is a vivid embodiment of the concept of "precision medicine" in modern medicine — from the traditional "broad-spectrum immunosuppression" to the current "precision targeted therapy," which is backed by in-depth exploration of disease mechanisms and continuous breakthroughs in medical technology.
This transformation not only greatly improves the treatment effect, enabling more moderate to severe patients to achieve skin lesion clearance and stable condition, but also reduces the risk of adverse reactions, making long-term treatment safer and more reassuring.
The rapid rise of Chinese innovative drugs not only demonstrates the R&D strength of local biopharmaceutical enterprises but also makes precision treatment more accessible and cost-effective, allowing more Chinese psoriasis patients to enjoy the benefits of cutting-edge treatment without relying on imported drugs.
In the future, with the continuous in-depth of R&D, it is believed that more domestic innovative biological drugs will emerge, bringing more precise and high-quality treatment options for psoriasis patients, allowing every patient to get rid of the trouble of psoriasis and regain confidence and a healthy life.
📌 Warm Reminder: All the above drugs are prescription drugs. Specific medication must be carried out under the guidance of a doctor. Before medication, it is necessary to screen for related risks such as infection. Do not use drugs without authorization.
No comments:
Post a Comment